Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease

6 Nov 2019

Abstract excerpt

To date, the development of disease-modifying therapies for Alzheimer's disease (AD) has largely focused on the removal of amyloid beta Aβ fragments from the CNS. Proteomic profiling of patient fluids may help identify novel therapeutic targets and biomarkers associated with AD pathology. Here, we applied the Olink™ ProSeek immunoassay to measure 270 CSF and plasma proteins across 415 Aβ- negative cognitively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Dementia and Cognitive Impairment Research
Share to GDF15 and Related Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31694701
DOI: 10.1186/s40478-019-0795-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s diseasePMID 31694701Read ↗

Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma ProteomicsSemantic proximity Read ↗

Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s diseaseSemantic proximity Read ↗

Proteomic Subtyping of Alzheimer’s Disease CSF links Blood-Brain Barrier Dysfunction to Reduced levels of Tau and Synaptic BiomarkersSemantic proximity Read ↗

Plasma and CSF proteomic signatures related to Alzheimer’s, α-synuclein, or vascular pathologies and clinical declineSemantic proximity Read ↗

Biomarker-informed CSF proteomics reveals ENPP2–LPA lipid signaling associated with Alzheimer’s diseaseSemantic proximity Read ↗

High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed dementia cohortSemantic proximity Read ↗

A genetic and proteomic comparison of key AD biomarkers across tissuesSemantic proximity Read ↗

Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profilesSemantic proximity Read ↗

Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer’s disease: A literature reviewSemantic proximity Read ↗

Deep Plasma Proteomics Reveals Shared and Disease-Specific Molecular Signatures in Alzheimer’s Disease and Frontotemporal DementiaSemantic proximity Read ↗

Multi-tissue proteomic signatures of Alzheimer’s disease: a systematic investigation in brain, CSF, blood and an exploratory study in tearsSemantic proximity Read ↗

Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later lifeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.